Boston Scientific Corporation (BSX) income statement
NYSE · Healthcare · Medical - Devices · 59,000 employees · CEO Michael F. Mahoney
- Price
- $41.98 -1.66%
- Market cap
- $60.8B
- Enterprise value
- $72.9B
- Last report
- Q3 '26 filed 2026-09-30
- Next report
- 2027-02-03 EPS est. $0.79
Boston Scientific Corporation (BSX) reported revenue of $5.14B for Q3 '26 (+1.4% year on year), operating income of $979M (19.1% of revenue) and net income of $578M. Over the last four quarters revenue was $21.1B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.73B | $3.86B | $4.12B | $4.21B | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B | $5.2B | $5.44B | $5.14B | |
| Cost of revenue | $1.41B | $1.47B | $1.54B | $1.56B | $1.89B | $1.71B | $1.64B | $1.52B | $1.35B | $1.59B | $1.59B | $1.71B | |
| Gross profit | $2.31B | $2.38B | $2.59B | $2.65B | $2.67B | $2.95B | $3.42B | $3.54B | $3.94B | $3.61B | $3.85B | $3.43B | |
| Research & development | $363M | $366M | $383M | $407M | $460M | $443M | $526M | $514M | $569M | $516M | $554M | $520M | |
| Other operating expenses | $12M | $10M | $9M | $5M | $10M | $14M | $363M | $237M | $328M | $244M | $313M | $246M | |
| Operating expenses | $1.75B | $1.74B | $1.84B | $1.97B | $2.08B | $2.05B | $2.61B | $2.49B | $2.73B | $2.54B | $2.67B | $2.45B | |
| Operating income | $558M | $644M | $747M | $674M | $589M | $896M | $819M | $1.05B | $1.21B | $1.07B | $1.18B | $979M | |
| Interest income | $22M | $0 | $0 | $0 | $22M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Interest expense | $67M | $72M | $81M | $83M | $139M | $87M | $90M | $87M | $90M | $90M | $96M | $100M | |
| Other non-operating income (gains on investments, FX ...) | -$14M | -$36M | $246M | -$77M | -$134M | $4M | -$212M | $24M | $250M | -$180M | $22M | $0 | |
| Total non-operating income | -$53M | -$36M | -$327M | -$6M | -$4M | -$91M | $122M | -$111M | -$506M | $90M | -$118M | -$246M | |
| Income before tax | $505M | $608M | $420M | $668M | $585M | $805M | $941M | $939M | $700M | $1.16B | $1.06B | $733M | |
| Income tax | $1M | $115M | $98M | $200M | $23M | $133M | $146M | $183M | $31M | -$176M | $155M | $153M | |
| Net income | $504M | $494M | $324M | $469M | $566M | $674M | $793M | $755M | $668M | $1.34B | $907M | $578M | |
| EPS (basic) | $0.34 | $0.34 | $0.22 | $0.32 | $0.38 | $0.46 | $0.54 | $0.51 | $0.45 | $0.90 | $0.62 | $0.40 | |
| EPS (diluted) | $0.34 | $0.33 | $0.22 | $0.32 | $0.38 | $0.45 | $0.53 | $0.50 | $0.45 | $0.90 | $0.61 | $0.40 | |
| Shares (basic, weighted) | 1.47B | 1.47B | 1.47B | 1.47B | 1.47B | 1.48B | 1.48B | 1.48B | 1.48B | 1.48B | 1.48B | 1.45B | |
| Shares (diluted, weighted) | 1.48B | 1.48B | 1.48B | 1.49B | 1.49B | 1.49B | 1.49B | 1.5B | 1.5B | 1.5B | 1.48B | 1.45B | |
| Depreciation & amortization | $313M | $304M | $311M | $306M | $348M | $325M | $336M | $342M | $365M | $351M | $355M | $0 | |
| EBITDA | $885M | $984M | $812M | $1.06B | $1.07B | $1.22B | $1.37B | $1.37B | $1.32B | $1.6B | $1.51B | $979M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.39B | $9.05B | $9.82B | $10.7B | $9.91B | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B | |
| Cost of revenue | $3.04B | $3.18B | $3.35B | $3.86B | $4.34B | $4.43B | $4.97B | $5.41B | $6.48B | $6.22B | |
| Gross profit | $5.34B | $5.87B | $6.48B | $6.88B | $5.58B | $7.46B | $7.71B | $8.83B | $10.3B | $13.9B | |
| Research & development | $920M | $997M | $1.11B | $1.17B | $1.14B | $1.2B | $1.32B | $1.41B | $1.62B | $2.05B | |
| Other operating expenses | $104M | $68M | $70M | $65M | $45M | $49M | $47M | $46M | $33M | $943M | |
| Operating expenses | $4.11B | $4.35B | $4.74B | $5.17B | $4.98B | $5.54B | $5.89B | $6.65B | $7.63B | $9.88B | |
| Operating income | $1.24B | $1.53B | $1.74B | $1.71B | $601M | $1.92B | $1.82B | $2.18B | $2.64B | $3.97B | |
| Interest income | $5M | $5M | $3M | $30M | $3M | $4M | $10M | $22M | $107M | $0 | |
| Interest expense | $234M | $230M | $269M | $513M | $468M | $349M | $464M | $272M | $387M | $349M | |
| Other non-operating income (gains on investments, FX ...) | $825M | $362M | $46M | $512M | $212M | $497M | $219M | -$76M | -$34M | $237M | |
| Total non-operating income | -$1.06B | -$592M | -$315M | -$1.03B | -$680M | -$846M | -$683M | -$196M | -$353M | -$586M | |
| Income before tax | $177M | $933M | $1.42B | $687M | -$79M | $1.08B | $1.14B | $1.99B | $2.28B | $3.39B | |
| Income tax | -$170M | $828M | -$249M | -$4.01B | $2M | $36M | $443M | $393M | $436M | $493M | |
| Net income | $347M | $104M | $1.67B | $4.7B | -$82M | $1.04B | $698M | $1.59B | $1.85B | $2.89B | |
| EPS (basic) | $0.26 | $0.08 | $1.21 | $3.38 | -$0.08 | $0.69 | $0.45 | $1.08 | $1.26 | $1.96 | |
| EPS (diluted) | $0.25 | $0.07 | $1.19 | $3.33 | -$0.08 | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | |
| Shares (basic, weighted) | 1.36B | 1.37B | 1.38B | 1.39B | 1.42B | 1.42B | 1.43B | 1.45B | 1.47B | 1.48B | |
| Shares (diluted, weighted) | 1.38B | 1.39B | 1.4B | 1.41B | 1.42B | 1.43B | 1.44B | 1.46B | 1.49B | 1.49B | |
| Depreciation & amortization | $815M | $844M | $894M | $1.01B | $1.12B | $1.09B | $1.14B | $1.2B | $1.27B | $1.37B | |
| EBITDA | $1.23B | $2.01B | $2.59B | $2.21B | $1.51B | $2.52B | $2.74B | $3.45B | $3.94B | $5.1B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-01